AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. See why AZN stock is a Buy.

AstraZeneca is running a trio of phase 3 trials for tozorakimab in patients with a history of COPD exacerbations, with data set to read out “after 2025,” Brindicci said.

Tozorakimab (MEDI3506, AstraZeneca) is an anti-IL-33 monoclonal antibody, according to the poster. “The FRONTIER-4 study results show encouraging clinical efficacy signals for tozorakimab as a ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

AstraZeneca (NASDAQ:AZN ... including camizestrant, baxdrostat, tozorakimab, and eneboparatide. At the same time, when forecasting the growth rates of the company's revenue and operating income ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...